RLMD HealthcareBeta data

Relmada Therapeutics, Inc.

$4.27+11.20%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 455.5M USD
Enterprise value: 237.7M USD
Full-time employees: 17

Overall health

Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Not enough data: growth

Would rank #552 of 1,157 fully scored healthcare companies (top 48%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 254% from December 2022 to August 2026.
Relmada Therapeutics had 254% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Relmada Therapeutics had 254% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Relmada Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss over the last 12 months.
Relmada Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

53/ 100

Oct 5 53 → Nov 4 53

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

33/100

Weak

2/3 inputs reported · Partial data

Since last quarter: ▼ Weaker

Share count up 274.3% (existing holders diluted)

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-21.5%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yieldUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0401 · MAD: 0.0401

Free cash flow yield-10.1%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield45.3%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 0 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

27/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-2.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.70Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-26.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.09Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-55.7%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.45

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.51Sector median: 0.6250 · MAD: 0.3380

Current ratio29.52×

Yahoo FinanceOutlier capped at sector 5th/95th percentile33% base weight · Z-score 11.07Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Relmada Therapeutics

Is Relmada Therapeutics getting weaker?: Its latest SEC filing (Aug 6, 2026) got weaker in some ways: 12-month revenue fell 34.5%; share count up 274.3%. Its overall score is unchanged at 53/100 since Oct 28, 2026.
How is Relmada Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -21.5% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -21.5% vs peers 1.5% (weaker than 100% of peers).
Is Relmada Therapeutics growing?: Insufficient data: 0 of 3 inputs reported (at least 2 needed).
How profitable is Relmada Therapeutics?: Less profitable than most of its peers. Profitability scores 27/100 against 1,393 healthcare peers. Return on invested capital -26.4% vs a peer median of 4.7% (weaker than 81% of peers).Return on invested capital -26.4% vs peers 4.7% (weaker than 81% of peers).
How risky is Relmada Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 29.52× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 29.52× vs peers 2.59× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Feb 28, 2014 · filed Aug 6, 2026 · compared with the quarter ended Nov 30, 2013

Got weaker

12-month revenue fell 34.5%
Share count up 274.3% (existing holders diluted)

	Previous quarter	Latest quarter	Change
Revenue (12 months)	4,830 USD	3,166 USD	−34.5%
Net income (12 months)	−50,369 USD	−4.5M USD	+8913.9%
Operating margin	-1042.8%	-2057272.2%	−2056229.4 pts
Free cash flow (12 months)	−24,280 USD	−228.0M USD	+939124.2%
Shares outstanding	28.5M	106.7M	+274.3%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Return on assets (ROA)	-56.3%	-102.7%	-101.3%	-174.6%	-61.0%	▲ 114 pts
Return on equity (ROE)	-60.4%	-111.8%	-115.7%	-225.2%	-66.3%	▲ 159 pts
Current ratio	14.83×	12.26×	8.00×	4.45×	14.62×	▲ 228%
Debt to equity	—	—	—	—	—	—

RLMD price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Not enough data: growth

Would rank #552 of 1,157 fully scored healthcare companies (top 48%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 254% from December 2022 to August 2026.

Relmada Therapeutics had 254% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Relmada Therapeutics had 254% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Relmada Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss over the last 12 months.

Relmada Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Relmada Therapeutics

Is Relmada Therapeutics getting weaker?

Its latest SEC filing (Aug 6, 2026) got weaker in some ways: 12-month revenue fell 34.5%; share count up 274.3%. Its overall score is unchanged at 53/100 since Oct 28, 2026.

How is Relmada Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -21.5% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -21.5% vs peers 1.5% (weaker than 100% of peers).

Is Relmada Therapeutics growing?

Insufficient data: 0 of 3 inputs reported (at least 2 needed).

How profitable is Relmada Therapeutics?

Less profitable than most of its peers. Profitability scores 27/100 against 1,393 healthcare peers. Return on invested capital -26.4% vs a peer median of 4.7% (weaker than 81% of peers).Return on invested capital -26.4% vs peers 4.7% (weaker than 81% of peers).

How risky is Relmada Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 29.52× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 29.52× vs peers 2.59× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

4,830 USD

3,166 USD

−34.5%

Net income (12 months)

−50,369 USD

−4.5M USD

+8913.9%

Operating margin

-1042.8%

-2057272.2%

−2056229.4 pts

Free cash flow (12 months)

−24,280 USD

−228.0M USD

+939124.2%

Shares outstanding

28.5M

106.7M

+274.3%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Return on assets (ROA)

-56.3%

-102.7%

-101.3%

-174.6%

-61.0%

▲ 114 pts

Return on equity (ROE)

-60.4%

-111.8%

-115.7%

-225.2%

-66.3%

▲ 159 pts

Current ratio

14.83×

12.26×

8.00×

4.45×

14.62×

▲ 228%

Debt to equity

—